Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG; and Accredo specialty pharmacy to distribute TEGSEDI, a subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
Previous Symbol
CUSIPN/A
Phone617-207-0202
Debt
Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.64
Price-To-Earnings
Trailing P/E Ratio-13.39
Forward P/E Ratio-11.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.21 million
Price / Sales48.44
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.70 per share
Price / Book11.10
Profitability
EPS (Most Recent Fiscal Year)($2.24)
Net Income$-109,750,000.00
Net Margins-245.68%
Return on Equity-77.04%
Return on Assets-53.39%
Miscellaneous
Employees100
Outstanding Shares89,260,000
Market Cap$2.72 billion
OptionableOptionable
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics Inc (NASDAQ:AKCA) announced its quarterly earnings data on Monday, November, 5th. The company reported ($0.73) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.07. The company had revenue of $19.24 million for the quarter, compared to analysts' expectations of $20.52 million. Akcea Therapeutics had a negative return on equity of 77.04% and a negative net margin of 245.68%. Akcea Therapeutics's revenue for the quarter was up 94.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.33) EPS. View Akcea Therapeutics' Earnings History.
When is Akcea Therapeutics' next earnings date?
What price target have analysts set for AKCA?
6 analysts have issued 12 month price targets for Akcea Therapeutics' stock. Their predictions range from $31.00 to $46.00. On average, they expect Akcea Therapeutics' share price to reach $40.50 in the next year. This suggests a possible upside of 35.2% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.
What is the consensus analysts' recommendation for Akcea Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.
Has Akcea Therapeutics been receiving favorable news coverage?
News headlines about AKCA stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akcea Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Nektar Therapeutics (NKTR), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Amarin (AMRN), Catalent (CTLT) and Amneal Pharmaceuticals (AMRX).
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO & Director (Age 50)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
- Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
- Ms. Sarah Boyce, Pres & Director (Age 46)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), BB Biotech AG (2.68%), BlackRock Inc. (2.21%), Vanguard Group Inc. (1.34%), Vanguard Group Inc (1.33%) and EcoR1 Capital LLC (0.85%). View Institutional Ownership Trends for Akcea Therapeutics.
Which major investors are selling Akcea Therapeutics stock?
AKCA stock was sold by a variety of institutional investors in the last quarter, including BB Biotech AG, Virtus ETF Advisers LLC, Alliancebernstein L.P., Wells Fargo & Company MN, TIAA CREF Investment Management LLC, BlackRock Inc., Bank of New York Mellon Corp and Credit Suisse AG. View Insider Buying and Selling for Akcea Therapeutics.
Which major investors are buying Akcea Therapeutics stock?
AKCA stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, FMR LLC, PNC Financial Services Group Inc., Bellevue Group AG, Morgan Stanley, Vanguard Group Inc, Vanguard Group Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Akcea Therapeutics.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $29.96.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $2.72 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.
What is Akcea Therapeutics' official website?
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
